HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of venous thromboembolism in general surgery.

Abstract
Venous thromboembolism continues to be an important cause of death in hospitalized patients undergoing major elective surgery. A study of autopsy-proven pulmonary embolism in hospital patients showed that venous thromboembolism accounted for 10% of deaths and that recognition of non-fatal thromboembolism continues to be a problem. The incidence of deep vein thrombosis increases with ageing, the annual rate per 1000 being one to three for those aged between 65 and 69 years and from two to eight for those aged between 85 and 89 years. The introduction of low-molecular-weight heparins has resulted in important changes in the management and prophylaxis of venous thromboembolism. Low-molecular-weight heparin preparations reduce the overall incidence of deep vein thrombosis in general surgery by at least 70%. Furthermore, the effect of low-molecular-weight heparin against pulmonary embolism is at least as great as that of low-dose unfractionated heparin. The incidence of serious and minor haemorrhagic events with low-molecular-weight heparin is similar to that with low-dose unfractionated heparin. Prophylaxis is started pre-operatively, and the usual duration for the post-operative period has been 7 days, or until the patient is discharged from the hospital. In conclusion, low-molecular-weight heparin is highly effective in preventing post-operative venous thromboembolism.
AuthorsV V Kakkar, F De Lorenzo
JournalBailliere's clinical haematology (Baillieres Clin Haematol) Vol. 11 Issue 3 Pg. 605-19 (Sep 1998) ISSN: 0950-3536 [Print] England
PMID10331095 (Publication Type: Journal Article, Review)
Chemical References
  • Anticoagulants
  • Heparin, Low-Molecular-Weight
Topics
  • Aged
  • Aged, 80 and over
  • Anticoagulants (adverse effects, therapeutic use)
  • Heparin, Low-Molecular-Weight (adverse effects, therapeutic use)
  • Humans
  • Postoperative Complications (prevention & control)
  • Pulmonary Embolism (etiology, prevention & control)
  • Venous Thrombosis (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: